Publications by authors named "James M Termini"

Claim this Profile
T
Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies.
Sebastian P Fuchs, Paula G Mondragon, Rachel Zabizhin, Shallu Tomer, Li Wang, James M Termini

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity.
James M Termini, José M Martinez-Navio, Guangping Gao, Sebastian P Fuchs, Ronald C Desrosiers

Mol Ther Methods Clin Dev· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy.
Suresh Pallikkuth, Hector Bolivar, Mary A Fletcher, Dunja Z Babic, Lesley R De Armas, James M Termini

Vaccine· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simian T Lymphotropic Virus 1 Infection of Papio anubis: Sequence Heterogeneity and T Cell Recognition.
James M Termini, Diogo M Magnani, Helen S Maxwell, William Lauer, Iris Castro

J Virol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Immunodeficiency Virus and Simian Immunodeficiency Virus Maintain High Levels of Infectivity in the Complete Absence of Mucin-Type O-Glycosylation.
James M Termini, Elizabeth S Church, Zachary A Silver, Stuart M Haslam, Anne Dell

J Virol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.
James M Termini, Sachin Gupta, Francesca N Raffa, Elizabeth Guirado, Margaret A Fischl

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HEK293T cell lines defective for O-linked glycosylation.
James M Termini, Zachary A Silver, Bryony Connor, Aristotelis Antonopoulos, Stuart M Haslam

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constitutively Active MAVS Inhibits HIV-1 Replication via Type I Interferon Secretion and Induction of HIV-1 Restriction Factors.
Sachin Gupta, James M Termini, Biju Issac, Elizabeth Guirado, Geoffrey W Stone

PLoS One· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Sachin Gupta, James M Termini, Yaelis Rivas, Miguel Otero, Francesca N Raffa

Vaccine· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Sachin Gupta, Emily S Clark, James M Termini, Justin Boucher, Saravana Kanagavelu

J Virol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
Saravana Kanagavelu, James M Termini, Sachin Gupta, Francesca N Raffa, Katherine A Fuller

PLoS One· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Sachin Gupta, James M Termini, Francesca N Raffa, Cindi-Ann Williams, Richard S Kornbluth

J Virol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.
Sachin Gupta, James M Termini, Saravana Kanagavelu, Geoffrey W Stone

Immunol Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
Saravana K Kanagavelu, Victoria Snarsky, James M Termini, Sachin Gupta, Suzanne Barzee

Vaccine· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.
Sachin Gupta, James M Termini, Liguo Niu, Saravana K Kanagavelu, Helena Schmidtmayerova

J Leukoc Biol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Latent Membrane Protein 1 as a molecular adjuvant for single-cycle lentiviral vaccines.
Sachin Gupta, James M Termini, Liguo Niu, Saravana K Kanagavelu, Andrew R Rahmberg

Retrovirology· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.
Liguo Niu, James M Termini, Saravana K Kanagavelu, Sachin Gupta, Morgane M Rolland

Vaccine· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis